You are here : Home > BGE Lab > Genetics and Chemogenomics team

Genetics and Chemogenomics team

Published on 27 June 2018


Marie-Odile Fauvarque
Laboratoire Biologie à Grande Échelle
Institut de Biosciences et Biotechnologies de Grenoble
17 avenue des Martyrs
38 054 Grenoble cedex 09

Composition of the team

Laurence Aubry, PhD
Caroline Barette, PhD, Automated screening of compounds libraries
Gilles Courtois, PhD
Marjorie Comte, Engineer
Julie Bourget, administrative
Marie-Odile Fauvarque, PhD
Agnès Journet, PhD
Magda Mortier, Assistant
Catherine Pillet, Technician
Emmanuelle Soleilhac, PhD, Cell profiling using automated microscopy
Emmanuel Taillebourg, PhD
Waltrich Augusto Thierry, PhD student

The CMBA: member of the CHEMBIOFRANCE national infrastructure
The Center for the screening for BioActive Molecules (CMBA) of the BGE laboratory participates to the recent very large research infrastructure (TGIR) ChemBioFrance. This infrastructure was designed to encourage and stimulate exchanges and services at the interfaces between the chemistry of biology and chemoinformatics in order to select bioactive molecules that can be used for basic or therapeutic research purposes. ChemBioFrance is a distributed infrastructure that interconnects the national chemical library, the platforms for the screening and the pharmacokinetic studies (ADME), and molecular modeling laboratories (chemoinformatics). It is open to researchers from academic and private laboratories.
Contact CEA/DRF/BIG: Marie-Odile Fauvarque
More information.


The team develops genetics and chemogenomics approaches for the identification and study of proteins and small chemicals functions in cell signalling. The team pursues both a research project which aims in the characterization of novel mechanisms of regulation of innate immune and inflammatory signals, and facilities and R&D activities at the Center for the screening for BioActive Molecules (CMBA).

The research activity of the team aims in bringing fundamental knowledge on deubiquitinases (DUBs) functions in the control of innate immune response and inflammation by using prospective genetics approaches in Drosophila. Results are then transposed to human cells. These DUBs are potential biological targets for the finding of small molecules modifying inflammatory response or tumorigenesis. DUBs are indeed implicated in several pathologies including chronic inflammation, neuron loss and cancer although their substrates and partners are still poorly described.

The CMBA center, labelled IBiSA in partnership with the group « Chimie Combinatoire et Criblage à Haut Débit » based at CEA-Saclay (CCHD/iBiTec-S) pursues a triple objective:

• Facilities and collaborative activities for the High Throughput Screening (HTS) of chemicals libraries on cellular or biochemical assays, including statistical analysis of the results,
• A Research & Development activity for improving the analysis of cell phenotypes by High Content Screening imaging (HCS), including statistical analysis of results,
• A training activity on HTS and HCS.

In addition to their therapeutic potential, small molecules present many advantages for research purposes. They are irreplaceable tools for probing dynamic phenomena and inducing reversible effects.

Key words

Automated screens; Cell imaging; Small chemical molecules; Cell signalling; Innate immunity; NF-ΚB; Ubiquitin proteases; Oncogenesis; Cancer